Completeness of American Cancer Registry Treatment Data: Implications for Quality of Care Research.

Commission on Cancer, American College of Surgeons, Chicago, IL.
Journal of the American College of Surgeons (Impact Factor: 4.45). 01/2013; 216(3). DOI: 10.1016/j.jamcollsurg.2012.12.016
Source: PubMed

ABSTRACT BACKGROUND: Evaluating and improving the quality of cancer care requires complete information on cancer stage and treatment. Hospital-based registries are a key tool in this effort, but reports in the 1990s showed that they fail to identify a major fraction of outpatient-administered treatment, including chemotherapy, endocrine therapy, and radiation. This can limit their value for evaluating patterns and quality of care. To determine the completeness of registry data in more recent years, we linked administrative claims from 2 private payers in Ohio to the National Cancer Data Base and Ohio Cancer Incidence and Surveillance System. METHODS: Incident breast and colorectal cancers among Ohio residents diagnosed in 2004-2006 were identified from linkage of the National Cancer Data Base, Ohio Cancer Incidence and Surveillance System, and payer insurance claims using ICD-9 and CPT procedure codes, and ICD-9 diagnosis codes. Linkage was accomplished using patient demographics, surgery dates, and hospital facility. Treatment found in claims and registry data were compared and assessed using the κ statistic. RESULTS: The analytic cohort included 2,552 breast and 822 colorectal cases. Results showed high agreement for breast surgery type, and moderately high agreement for colorectal surgery type. For breast cases, the registries captured 87% of chemotherapy, 86% of radiation, and 64% of endocrine treatment in claims. For colorectal cases, the registry captured 83% of chemotherapy and 84% of radiation in claims. CONCLUSIONS: Hospital-based registries for breast and colon cancer diagnosed in 2004-2006 captured about 85% of radiation and chemotherapy data compared with claims data, a higher percentage than earlier reports. These findings provide direction and a cautionary note to those using registry data for study of patterns and quality of systemic and radiation therapy care.

  • Source
    • "Second, missing chemotherapy data were infrequent and did not differ between this study's Ontario and California cohorts. Third, analyses of insurers, hospital-based surgeries, and survival were unlikely to have been affected (Chan, Gomez, O'Malley, Perkins, & Clark, 2006; Hall, Schulze, Groome, Mackillop, & Holowaty , 2006; Li, King, deGara, White, & Winget, 2012; Mallin et al., 2013; Verrill, 2010), and any modest errors very likely did not differ by socioeconomic factors (Chan et al., 2006). Such modest nondifferential errors on exposures, mediators, or outcomes suggest that any bias of findings would probably have been toward the null (Blakely, McKenzie, & Carter, 2013; Copeland, Checkoway, McMichael, & Holbrook, 1977; Jurek, Greenland, & Maldonado, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Extremely poor Canadian women were recently observed to be largely advantaged on most aspects of breast cancer care as compared with similarly poor, but much less adequately insured, women in the United States. This historical study systematically replicated the protective effects of single- versus multipayer health care by comparing colon cancer care among cohorts of extremely poor women in California and Ontario between 1996 and 2011. The Canadian women were again observed to have been largely advantaged. They were more likely to have received indicated surgery and chemotherapy, and their wait times for care were significantly shorter. Consequently, the Canadian women were much more likely to experience longer survival times. Regression analyses indicated that health insurance nearly completely explained the Canadian advantages. Implications for contemporary and future reforms of U.S. health care are discussed.
    Health & social work 11/2013; 38(4):240-8. DOI:10.1093/hsw/hlt022 · 0.94 Impact Factor
  • Journal of Oncology Practice 05/2013; 9(3):149-51. DOI:10.1200/JOP.2013.000955
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Quercetin is a hydrophobic agent with potential anticancer activity. The aim of the present study was to observe the effects of quercetin on the proliferation of the breast cancer cell line MCF-7 and the gene expression of survivin. The molecular mechanism underlying the antiproliferative effect of quercetin was also investigated. MCF-7 breast cancer cells were treated with various concentrations of quercetin. The inhibitory effect of quercetin on proliferation was detected using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and the inhibition rate was calculated. Cellular apoptosis was detected by immunocytochemistry and survivin mRNA expression levels were observed using reverse transcription-polymerase chain reaction (RT-PCR). Western blot analysis was used to analyze changes in the expression levels of survivin protein. Quercetin induced the apoptosis of MCF-7 cells and inhibited the proliferation of the MCF-7 breast cancer cells in a time- and concentration-dependent manner. The mRNA and protein expression levels of survivin were reduced as the concentration of quercetin increased. Quercetin inhibited the growth of MCF-7 cells and promoted apoptosis by inducing G0/ G1 phase arrest. It also regulated the expression of survivin mRNA in MCF-7 cells, which may be the mechanism underlying its antitumor effect.
    Experimental and therapeutic medicine 11/2013; 6(5):1155-1158. DOI:10.3892/etm.2013.1285 · 0.94 Impact Factor
Show more